SCHEMBL7046148

SCHEMBL7046148

COc1nn(-c2ccc(NC(=O)OCc3ccccc3Cl)c(C)c2)c(=O)o1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.78
FAAH O00519 2/20 0.78
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
CASP3 P42574 1/20 0.43
KMT2A Q03164 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
SCN9A Q15858 2/20 0.43
SCN5A Q14524 1/20 0.43
CYP1A2 P05177 3/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2C19 P33261 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RECQL P46063 1/20 0.41
ABHD16A O95870 2/20 0.41
LPL P06858 1/20 0.41
LIPC P11150 1/20 0.41
LIPE Q05469 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29499689 0.88 MGLL (1.00) MGLLFAAHSMN1; SMN2ABHD16ALPL
SCHEMBL7042914 0.88 MGLL (1.00) MGLLFAAHSMN1; SMN2ABHD16ALPL
SCHEMBL6615026 0.84 MGLL (0.75) MGLLFAAHSMN1; SMN2ABHD16ALPL
SCHEMBL7043936 0.82 MGLL (0.82) MGLLFAAHMEN1KMT2ASMN1; SMN2
SCHEMBL7046042 0.81 MGLL (0.72) MGLLFAAHSCN9ASMN1; SMN2ABHD16A
SCHEMBL7046095 0.81 MGLL (0.74) MGLLFAAHKMT2AABHD16ALPL
SCHEMBL7571649 0.80 MGLL (0.72) MGLLFAAHSMN1; SMN2ABHD16ALPL
SCHEMBL7046374 0.79 MGLL (0.83) MGLLFAAHSMN1; SMN2LIPCLIPE
SCHEMBL7040893 0.79 MGLL (0.83) MGLLFAAHCASP3SMN1; SMN2LIPC
SCHEMBL7039924 0.78 MGLL (0.81) MGLLFAAHSMN1; SMN2LIPCLIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 MGLL 1542/4885FAAH 46/4885MEN1 3352/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE MGLL 10/4885FAAH 142/4885MEN1 4309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.